Geneos Wealth Management’s Adtran ADTN Stock Holding History

Geneos Wealth Management’s Portfolio ADTN Stock Details ADTN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-500	Closed	-$11K	–	2743
2021 Q4	$11K	Buy	+500	New	+$10.1K	﹤0.01%	2124

Other funds holding ADTN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

WHG

Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCA

Bernzott Capital Advisors Camarillo, California $209M AUM 9.57% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Geneos Wealth Management's ADTN Position: Q1 2022 in Review

Geneos Wealth Management sold out of Adtran (ADTN) in Q1 2022, closing a stake of 500 shares — an estimated $11K sold.

Geneos Wealth Management first reported a position in ADTN in Q4 2021 and held it in 1 quarter. The position peaked at $11K in Q4 2021. 187 funds tracked by Wall St. Rank hold ADTN as of Q1 2022.

Geneos Wealth Management reported no remaining Adtran position as of Q1 2022 after selling out during the quarter.
Geneos Wealth Management sold 500 Adtran shares in Q1 2022, an estimated $11K.
Geneos Wealth Management first reported a position in Adtran in Q4 2021 and held it in 1 quarter.
Geneos Wealth Management's Adtran position peaked at $11K in Q4 2021.
187 funds tracked by Wall St. Rank held Adtran as of Q1 2022.

Based on Geneos Wealth Management's 13F filing for Q1 2022, filed 16 May 2022.